We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy
Read MoreHide Full Article
Key Takeaways
Dyne Therapeutics submitted a BLA to the FDA for z-rostudirsen in DMD patients amenable to exon 51 skipping.
Dyne Therapeutics' BLA filing is backed by phase I/II data showing improved dystrophin and RFF velocity.
Dyne Therapeutics launched the phase III FORZETTO study to support full approval of z-rostudirsen.
Dyne Therapeutics (DYN - Free Report) announced the submission of a biologics license application (BLA) to the FDA seeking accelerated approval for zeleciment rostudirsen (z-rostudirsen/DYNE-251). The investigational therapy has been developed for ambulatory patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. Following the announcement, DYN’s shares rose 4.5% on Tuesday.
The proposed treatment regimen involves a 20 mg/kg intravenous dose administered once every four weeks.
The company has requested a Priority Review from the regulatory authority which could reduce the review timeline to six months compared with 10 months under standard review, following the FDA’s 60-day filing review period. If approved on schedule, the company expects to launch z-rostudirsen in the United States in the first quarter of 2027.
DMD is a rare, progressive neuromuscular disorder caused by mutations in the DMD gene, which result in little or no dystrophin production, a protein essential for muscle function. The disease usually begins in early childhood with muscle weakness and gradually worsens, impacting mobility and overall physical function.
Year to date, shares of DYN have declined 7.3% compared with the industry’s 6.4% fall.
Image Source: Zacks Investment Research
DYN Submits BLA Based on Phase I/II DELIVER Study
The BLA submission is supported by positive data from the registrational expansion cohort of the phase I/II DELIVER study which met its primary endpoint. The study demonstrated that treatment with z-rostudirsen led to a statistically significant increase in dystrophin production and clinically meaningful improvements in rise from floor (RFF) velocity versus placebo at six months, with a favorable safety profile. RFF is a key measure of muscle strength and motor function in DMD. At present, z-rostudirsen is being evaluated in the ongoing long-term extension phase of the DELIVER study.
Dyne Therapeutics initiated a global phase III FORZETTO study evaluating z-rostudirsen in DMD patients earlier this month. The primary endpoint is the change from baseline in RFF velocity. Secondary endpoints include several measures of motor and respiratory function, along with patient-reported outcomes.
Per management, Dyne has reached an agreement with the FDA on the design and protocol of the FORZETTO study, which is intended to serve as the confirmatory study supporting potential conversion of accelerated approval to full approval in the United States, as well as future regulatory filings in international markets.
Z-rostudirsen received several regulatory designations, including Breakthrough Therapy, Fast Track, Rare Pediatric Disease and Orphan Drug status from global health authorities.
Besides z-rostudirsen, Dyne is advancing additional preclinical DMD programs such as DYNE-253, DYNE-245, DYNE-244 and DYNE-255 targeting multiple exon-skipping mutations in DMD.
DYN’s Zacks Rank & Stocks to Consider
Dyne Therapeutics currently carries a Zacks Rank #3 (Hold).
Over the past 30 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have increased from $3.00 to $3.35. Over the same period, EPS estimates for 2027 have risen to $3.33 from $3.47. INDV shares have risen 5.4% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
Over the past 30 days, estimates for Liquidia’s 2026 earnings per share have increased to $2.97 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.81 from $2.91. LQDA shares have gained 74.3% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
Over the past 30 days, estimates for Immunocore’s 2026 loss per share have narrowed from 97 cents to 16 cents. Over the same period, estimates for 2027 have improved from a loss of 39 cents to earnings of 11 cents per share. IMCR shares have lost 15.3% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 46.66%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy
Key Takeaways
Dyne Therapeutics (DYN - Free Report) announced the submission of a biologics license application (BLA) to the FDA seeking accelerated approval for zeleciment rostudirsen (z-rostudirsen/DYNE-251). The investigational therapy has been developed for ambulatory patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. Following the announcement, DYN’s shares rose 4.5% on Tuesday.
The proposed treatment regimen involves a 20 mg/kg intravenous dose administered once every four weeks.
The company has requested a Priority Review from the regulatory authority which could reduce the review timeline to six months compared with 10 months under standard review, following the FDA’s 60-day filing review period. If approved on schedule, the company expects to launch z-rostudirsen in the United States in the first quarter of 2027.
DMD is a rare, progressive neuromuscular disorder caused by mutations in the DMD gene, which result in little or no dystrophin production, a protein essential for muscle function. The disease usually begins in early childhood with muscle weakness and gradually worsens, impacting mobility and overall physical function.
Year to date, shares of DYN have declined 7.3% compared with the industry’s 6.4% fall.
Image Source: Zacks Investment Research
DYN Submits BLA Based on Phase I/II DELIVER Study
The BLA submission is supported by positive data from the registrational expansion cohort of the phase I/II DELIVER study which met its primary endpoint. The study demonstrated that treatment with z-rostudirsen led to a statistically significant increase in dystrophin production and clinically meaningful improvements in rise from floor (RFF) velocity versus placebo at six months, with a favorable safety profile. RFF is a key measure of muscle strength and motor function in DMD. At present, z-rostudirsen is being evaluated in the ongoing long-term extension phase of the DELIVER study.
Dyne Therapeutics initiated a global phase III FORZETTO study evaluating z-rostudirsen in DMD patients earlier this month. The primary endpoint is the change from baseline in RFF velocity. Secondary endpoints include several measures of motor and respiratory function, along with patient-reported outcomes.
Per management, Dyne has reached an agreement with the FDA on the design and protocol of the FORZETTO study, which is intended to serve as the confirmatory study supporting potential conversion of accelerated approval to full approval in the United States, as well as future regulatory filings in international markets.
Z-rostudirsen received several regulatory designations, including Breakthrough Therapy, Fast Track, Rare Pediatric Disease and Orphan Drug status from global health authorities.
Besides z-rostudirsen, Dyne is advancing additional preclinical DMD programs such as DYNE-253, DYNE-245, DYNE-244 and DYNE-255 targeting multiple exon-skipping mutations in DMD.
DYN’s Zacks Rank & Stocks to Consider
Dyne Therapeutics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Indivior Pharmaceuticals (INDV - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy) and Immunocore (IMCR - Free Report) , which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 30 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have increased from $3.00 to $3.35. Over the same period, EPS estimates for 2027 have risen to $3.33 from $3.47. INDV shares have risen 5.4% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
Over the past 30 days, estimates for Liquidia’s 2026 earnings per share have increased to $2.97 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.81 from $2.91. LQDA shares have gained 74.3% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
Over the past 30 days, estimates for Immunocore’s 2026 loss per share have narrowed from 97 cents to 16 cents. Over the same period, estimates for 2027 have improved from a loss of 39 cents to earnings of 11 cents per share. IMCR shares have lost 15.3% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 46.66%.